| Ticker Details |
Corbus Pharmaceuticals Holdings, Inc. Common Stock
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
|
| IPO Date: |
November 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$200.76M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.36 | 4.35%
|
| Avg Daily Range (30 D): |
$0.21 | 2.27%
|
| Avg Daily Range (90 D): |
$0.31 | 3.14%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.26M |
| Avg Daily Volume (30 D): |
.29M |
| Avg Daily Volume (90 D): |
.39M |
| Trade Size |
| Avg Trade Size (Sh.): |
251 |
| Avg Trade Size (Sh.) (30 D): |
74 |
| Avg Trade Size (Sh.) (90 D): |
83 |
| Institutional Trades |
| Total Institutional Trades: |
457 |
| Avg Institutional Trade: |
$1.77M |
| Avg Institutional Trade (30 D): |
$.69M |
| Avg Institutional Trade (90 D): |
$2.04M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.11M |
| Avg Closing Trade (30 D): |
$.88M |
| Avg Closing Trade (90 D): |
$5.09M |
| Avg Closing Volume: |
53.73K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-6.11
|
$-1.81
|
$-1.23
|
|
Diluted EPS
|
$-6.11
|
$-1.81
|
$-1.23
|
|
Revenue
|
$5.1M
|
$1.16M
|
$1.4M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-101.9M
|
$-35.04M
|
$-22.97M
|
|
Operating Income / Loss
|
$-106.88M
|
$-36.19M
|
$-24.3M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$5.89M
|
$-5.41M
|
$M
|
|
PE Ratio
|
|
|
|
|
|
|
